Gu H - Search Results

1

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways.

Qu J, Hou Y, Chen Q, Chen J, Li Y, Zhang E, Gu H, Xu R, Liu Y, Cao W, Zhang J, Cao L, He J, Cai Z. Qu J, et al. Among authors: gu h. Oncogene. 2022 Jan;41(3):400-413. doi: 10.1038/s41388-021-02095-8. Epub 2021 Nov 10. Oncogene. 2022. PMID: 34759347 Free PMC article.

2

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.

He J, Chen Q, Gu H, Chen J, Zhang E, Guo X, Huang X, Yan H, He D, Yang Y, Zhao Y, Wang G, He H, Yi Q, Cai Z. He J, et al. Among authors: gu h. Haematologica. 2018 Aug;103(8):1369-1379. doi: 10.3324/haematol.2017.181172. Epub 2018 May 17. Haematologica. 2018. PMID: 29773595 Free PMC article.

3

The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.

Huang X, Gu H, Zhang E, Chen Q, Cao W, Yan H, Chen J, Yang L, Lv N, He J, Yi Q, Cai Z. Huang X, et al. Among authors: gu h. Int J Cancer. 2020 Apr 1;146(7):1963-1978. doi: 10.1002/ijc.32615. Epub 2019 Aug 24. Int J Cancer. 2020. PMID: 31390487 Free PMC article.

4

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

Wu X, Liu Y, Zhang E, Chen J, Huang X, Yan H, Cao W, Qu J, Gu H, Xu R, He J, Cai Z. Wu X, et al. Among authors: gu h. Oxid Med Cell Longev. 2020 Aug 15;2020:6096391. doi: 10.1155/2020/6096391. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32879652 Free PMC article.

5

Emerging agents and regimens for multiple myeloma.

Yang Y, Li Y, Gu H, Dong M, Cai Z. Yang Y, et al. Among authors: gu h. J Hematol Oncol. 2020 Nov 9;13(1):150. doi: 10.1186/s13045-020-00980-5. J Hematol Oncol. 2020. PMID: 33168044 Free PMC article. Review.

6

Metabolic reprogramming in macrophage responses.

Liu Y, Xu R, Gu H, Zhang E, Qu J, Cao W, Huang X, Yan H, He J, Cai Z. Liu Y, et al. Among authors: gu h. Biomark Res. 2021 Jan 6;9(1):1. doi: 10.1186/s40364-020-00251-y. Biomark Res. 2021. PMID: 33407885 Free PMC article. Review.

7

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis.

Liu Y, Yan H, Gu H, Zhang E, He J, Cao W, Qu J, Xu R, Cao L, He D, Zhang J, Hou Y, Cai Z. Liu Y, et al. Among authors: gu h. Oncoimmunology. 2022 Mar 31;11(1):2057837. doi: 10.1080/2162402X.2022.2057837. eCollection 2022. Oncoimmunology. 2022. PMID: 35371618 Free PMC article.

8

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.

Cao L, Chen Q, Gu H, Li Y, Cao W, Liu Y, Qu J, Hou Y, Chen J, Zhang E, He J, Cai Z. Cao L, et al. Among authors: gu h. Clin Epigenetics. 2022 Jul 7;14(1):84. doi: 10.1186/s13148-022-01306-7. Clin Epigenetics. 2022. PMID: 35799216 Free PMC article.

9

Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma.

Yan H, He D, Qu J, Liu Y, Xu R, Gu H, Chen J, Li Y, Zhang E, Zhao Y, He J, Cai Z. Yan H, et al. Among authors: gu h. Cancer Immunol Immunother. 2023 Feb;72(2):327-338. doi: 10.1007/s00262-022-03241-1. Epub 2022 Jul 26. Cancer Immunol Immunother. 2023. PMID: 35881196 Free PMC article.

10

Calcium silicate/bortezomib combinatory therapy for multiple myeloma.

Cao L, Gu H, Zhang Z, Zhang E, Chang J, Cai Z. Cao L, et al. Among authors: gu h. J Mater Chem B. 2023 Mar 1;11(9):1929-1939. doi: 10.1039/d2tb02009b. J Mater Chem B. 2023. PMID: 36744994

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,659 results

Search Page

Filters